Newsfeeds - Spark Newswire

2 minute read

Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents

February 1, 4:47 PM

After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc.

DMTTF

3 minute read

Small Pharma, Inc’s Psychedelics For Major Depression Trial Results And Q1 Earnings

By Lara Goldstein

January 25, 3:55 PM

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major Depressive Disorder (MDD).

DMTTF

2 minute read

This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage

By Lara Goldstein

December 22, 4:49 PM

Short-acting psychedelics biotech company Small Pharma Inc.

DMTTF

2 minute read

Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing

By Lara Goldstein

December 19, 1:47 PM

Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors (SSRIs) and proprietary lead DMT candidate SPL026 in patients with Major Depressive Disorder (MDD).

DMTTF